PIK3C3 and cancer: To identify potential VPS34 vulnerabilities in cancer cells we assessed cell growth after a 3 day treatment with the VPS34 inhibitor PIK-III across 306 cell lines from the Cancer Cell Line Encyclopedia (CCLE) [24].